PARIS, Jan. 29, 2016 (GLOBE NEWSWIRE) — NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| — 2015 Full-Year Results | March 7, 2016 | |||
| — Shareholders’ AGM | April 12, 2016 | |||
| — 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
CONTACT: Contacts Neovacs/ Charlène Masson +33 (0)1 53 10 93 00 cmasson@neovacs.com New Cap /Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 neovacs@newcap.eu Press / U.S. Inquiries – The Ruth Group Joanna Zimmerman / Joseph Green +1-646-536-7012 / 7013 jzimmerman@theruthgroup.com / jgreen@theruthgroup.com Investor Relations / Financial Communications Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu
